{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:49:18Z","timestamp":1790995758726,"version":"4.1.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s11154-008-9082-4","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T03:41:09Z","timestamp":1216352469000},"page":"91-102","source":"Crossref","is-referenced-by-count":75,"title":["Somatostatin and dopamine receptors as targets for medical treatment of Cushing\u2019s Syndrome"],"prefix":"10.1007","volume":"10","author":[{"given":"C.","family":"de Bruin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. W. J.","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. J.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,19]]},"reference":[{"issue":"12","key":"9082_CR1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJM199503233321207","volume":"332","author":"DN Orth","year":"1995","unstructured":"Orth DN. Cushing\u2019s syndrome. N Engl J Med 1995;332(12):791\u2013803.","journal-title":"N Engl J Med"},{"issue":"1","key":"9082_CR2","first-page":"117","volume":"86","author":"J Lindholm","year":"2001","unstructured":"Lindholm J, et al. Incidence and late prognosis of cushing\u2019s syndrome: a population-based study. J Clin Endocrinol Metab 2001;86(1):117\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9522","key":"9082_CR3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, et al. Cushing\u2019s syndrome. Lancet. 2006;367(9522):1605\u201317.","journal-title":"Lancet."},{"issue":"5","key":"9082_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2005.02380.x","volume":"63","author":"AB Atkinson","year":"2005","unstructured":"Atkinson AB, et al. Long-term remission rates after pituitary surgery for Cushing\u2019s disease: the need for long-term surveillance. Clin Endocrinol 2005;63(5):549\u201359.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"9082_CR5","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3171\/jns.2005.102.6.1004","volume":"102","author":"RJ Benveniste","year":"2005","unstructured":"Benveniste RJ, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 2005;102(6):1004\u201312.","journal-title":"J Neurosurg"},{"issue":"9","key":"9082_CR6","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1210\/jc.2004-2436","volume":"90","author":"M Locatelli","year":"2005","unstructured":"Locatelli M, Vance ML, Laws ER. Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing\u2019s disease. J Clin Endocrinol Metab 2005;90(9):5478\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9082_CR7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1023365200437","volume":"5","author":"AS Mahmoud-Ahmed","year":"2002","unstructured":"Mahmoud-Ahmed AS, Suh JH. Radiation therapy for Cushing\u2019s disease: a review. Pituitary 2002;5(3):175\u201380.","journal-title":"Pituitary"},{"issue":"2","key":"9082_CR8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ecl.2005.01.005","volume":"34","author":"ML Vance","year":"2005","unstructured":"Vance ML. Pituitary radiotherapy. Endocrinol Metab Clin North Am 2005;34(2):479\u201387. xi.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"9082_CR9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3171\/jns.2007.106.6.980","volume":"106","author":"J Jagannathan","year":"2007","unstructured":"Jagannathan J, et al. Gamma Knife surgery for Cushing\u2019s disease. J Neurosurg 2007;106(6):980\u20137.","journal-title":"J Neurosurg"},{"issue":"8","key":"9082_CR10","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1210\/jc.2004-2527","volume":"90","author":"I Ilias","year":"2005","unstructured":"Ilias I, et al. Cushing\u2019s syndrome due to ectopic corticotropin secretion: twenty years\u2019 experience at the National Institutes of Health. J Clin Endocrinol Metab 2005;90(8):4955\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9082_CR11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1210\/jc.2005-1542","volume":"91","author":"AM Isidori","year":"2006","unstructured":"Isidori AM, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2006;91(2):371\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9082_CR12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1749-6632.2002.tb04418.x","volume":"970","author":"D Morris","year":"2002","unstructured":"Morris D, Grossman A. The Medical management of Cushing\u2019s syndrome. Ann NY Acad Sci 2002;970(1):119\u201333.","journal-title":"Ann NY Acad Sci"},{"issue":"1","key":"9082_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","volume":"158","author":"F Castinetti","year":"2008","unstructured":"Castinetti F, et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease. Eur J Endocrinol 2008;158(1):91\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9082_CR14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1022308429992","volume":"5","author":"LK Nieman","year":"2002","unstructured":"Nieman LK. Medical therapy of Cushing\u2019s disease. Pituitary 2002;5(2):77\u201382.","journal-title":"Pituitary"},{"issue":"3","key":"9082_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/ENDO:20:3:255","volume":"20","author":"P Barnett","year":"2003","unstructured":"Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003;20(3):255\u201364.","journal-title":"Endocrine"},{"issue":"4","key":"9082_CR16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","volume":"12","author":"SW Lamberts","year":"1991","unstructured":"Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12(4):450\u201382.","journal-title":"Endocr Rev"},{"issue":"3","key":"9082_CR17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20(3):157\u201398.","journal-title":"Front Neuroendocrinol"},{"issue":"1","key":"9082_CR18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, et al. Dopamine receptors: from structure to function. Physiol Rev 1998;78(1):189\u2013225.","journal-title":"Physiol Rev"},{"issue":"2","key":"9082_CR19","first-page":"551","volume":"47","author":"JC Reubi","year":"1987","unstructured":"Reubi JC, et al. Somatostatin receptors in human endocrine tumors. Cancer Res 1987;47(2):551\u20138.","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"9082_CR20","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1530\/eje.1.02353","volume":"156","author":"R Pivonello","year":"2007","unstructured":"Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland LJ. Novel insights in dopamine receptor physiology. Eur J Endocrinol 2007;156(Supplement 1):S13\u2013S21.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"9082_CR21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0026-0495(75)90127-4","volume":"24","author":"G Giustina","year":"1975","unstructured":"Giustina G, et al. Dose-response study of the inhibiting effect of somatostatin on growth hormone and insulin secretion in normal subjects and acromegalic patients. Metabolism 1975;24(7):807\u201315.","journal-title":"Metabolism"},{"issue":"4","key":"9082_CR22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/edrv-9-4-417","volume":"9","author":"SW Lamberts","year":"1988","unstructured":"Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988;9(4):417\u201336.","journal-title":"Endocr Rev"},{"issue":"6","key":"9082_CR23","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1210\/jcem-60-6-1161","volume":"60","author":"SW Lamberts","year":"1985","unstructured":"Lamberts SW, et al. The somatostatin analog SMS 201\u2013995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985;60(6):1161\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"9082_CR24","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM198512193132504","volume":"313","author":"SW Lamberts","year":"1985","unstructured":"Lamberts SW, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201\u2013995. N Engl J Med 1985;313(25):1576\u201380.","journal-title":"N Engl J Med"},{"issue":"1","key":"9082_CR25","first-page":"140","volume":"86","author":"A Saveanu","year":"2001","unstructured":"Saveanu A, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86(1):140\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9082_CR26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707\u201316.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"9082_CR27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch ME, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60(4):698\u2013705.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9082_CR28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/14656566.1.3.555","volume":"1","author":"A Colao","year":"2000","unstructured":"Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother 2000;1(3):555\u201374.","journal-title":"Expert Opin Pharmacother"},{"issue":"5463","key":"9082_CR29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","volume":"288","author":"M Rocheville","year":"2000","unstructured":"Rocheville M, et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000;288(5463):154\u20137.","journal-title":"Science"},{"issue":"6","key":"9082_CR30","doi-asserted-by":"crossref","first-page":"E1044","DOI":"10.1152\/ajpendo.00209.2005","volume":"289","author":"D Ferone","year":"2005","unstructured":"Ferone D, et al. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin\u2013dopamine molecules on cell proliferation. Am J Physiol Endocrinol Metab 2005;289(6):E1044\u20131050.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"68","key":"9082_CR31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","volume":"179","author":"P Brazeau","year":"1973","unstructured":"Brazeau P, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179(68):77\u20139.","journal-title":"Science"},{"issue":"11","key":"9082_CR32","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1210\/endo.136.11.7588261","volume":"136","author":"AM O\u2019Carroll","year":"1995","unstructured":"O\u2019Carroll AM, Krempels K. Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endocrinology 1995;136(11):5224\u20137.","journal-title":"Endocrinology"},{"issue":"11","key":"9082_CR33","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1210\/endo.136.11.7588263","volume":"136","author":"R Day","year":"1995","unstructured":"Day R, et al. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology 1995;136(11):5232\u20135.","journal-title":"Endocrinology"},{"issue":"1","key":"9082_CR34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/endo.139.1.5807","volume":"139","author":"E Mezey","year":"1998","unstructured":"Mezey E, et al. Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology 1998;139(1):414\u20139.","journal-title":"Endocrinology"},{"issue":"5","key":"9082_CR35","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1210\/endo-114-5-1546","volume":"114","author":"MR Brown","year":"1984","unstructured":"Brown MR, Rivier C, Vale W. Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology 1984;114(5):1546\u20139.","journal-title":"Endocrinology"},{"issue":"5","key":"9082_CR36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000124203","volume":"41","author":"J Kraicer","year":"1985","unstructured":"Kraicer J, Gajewski TC, Moor BC. Release of pro-opiomelanocortin-derived peptides from the pars intermedia and pars distalis of the rat pituitary: effect of corticotrophin-releasing factor and somatostatin. Neuroendocrinology 1985;41(5):363\u201373.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"9082_CR37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000125200","volume":"50","author":"SW Lamberts","year":"1989","unstructured":"Lamberts SW, et al. Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 1989;50(1):44\u201350.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"9082_CR38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2265.1989.tb00272.x","volume":"30","author":"PJ Stafford","year":"1989","unstructured":"Stafford PJ, et al. The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects. Clin Endocrinol (Oxf) 1989;30(6):661\u20136.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7829","key":"9082_CR39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(73)92413-6","volume":"2","author":"R Hall","year":"1973","unstructured":"Hall R, et al. Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet 1973;2(7829):581\u20134.","journal-title":"Lancet"},{"key":"9082_CR40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/00365528609087435","volume":"119","author":"SL Lightman","year":"1986","unstructured":"Lightman SL, Fox P, Dunne MJ. The effect of SMS 201\u2013995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scand J Gastroenterol Suppl 1986;119:84\u201395.","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"5","key":"9082_CR41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-2007-1003660","volume":"23","author":"C Invitti","year":"1991","unstructured":"Invitti C, et al. Effect of sandostatin on CRF-stimulated secretion of ACTH, beta-lipotropin and beta-endorphin. Horm Metab Res 1991;23(5):233\u20135.","journal-title":"Horm Metab Res"},{"issue":"4","key":"9082_CR42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF01468882","volume":"54","author":"HL Fehm","year":"1976","unstructured":"Fehm HL, et al. Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin Wochenschr 1976;54(4):173\u20135.","journal-title":"Klin Wochenschr"},{"issue":"1","key":"9082_CR43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.bjp.0705235","volume":"139","author":"D Cervia","year":"2003","unstructured":"Cervia D, et al. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br J Pharmacol 2003;139(1):109\u201321.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"9082_CR44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/endo-108-1-281","volume":"108","author":"UI Richardson","year":"1981","unstructured":"Richardson UI, Schonbrunn A. Inhibition of adrenocorticotropin secretion by somatostatin in pituitary cells in culture. Endocrinology 1981;108(1):281\u201390.","journal-title":"Endocrinology"},{"issue":"4","key":"9082_CR45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/0306-4522(95)00510-2","volume":"71","author":"M Tallent","year":"1996","unstructured":"Tallent M, et al. Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2 + current in the pituitary cell line AtT-20. Neuroscience 1996;71(4):1073\u201381.","journal-title":"Neuroscience"},{"issue":"6","key":"9082_CR46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000059430","volume":"75","author":"MZ Strowski","year":"2002","unstructured":"Strowski MZ, et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 2002;75(6):339\u201346.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"9082_CR47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00210-003-0752-1","volume":"367","author":"D Cervia","year":"2003","unstructured":"Cervia D, Fehlmann D, Hoyer D. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi\/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs. Naunyn Schmiedebergs Arch Pharmacol 2003;367(6):578\u201387.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"9082_CR48","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J Hoek van der","year":"2005","unstructured":"van der Hoek J, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005;289(2):E278\u2013287.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"9082_CR49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1210\/endo-110-4-1147","volume":"110","author":"A Schonbrunn","year":"1982","unstructured":"Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 1982;110(4):1147\u201354.","journal-title":"Endocrinology"},{"issue":"2","key":"9082_CR50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","volume":"130","author":"GK Stalla","year":"1994","unstructured":"Stalla GK, et al. Octreotide exerts different effects in vivo and in vitro in Cushing\u2019s disease. Eur J Endocrinol 1994;130(2):125\u201331.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"9082_CR51","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152(4):645\u201354.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"9082_CR52","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006;91(11):4482\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"9082_CR53","first-page":"2976","volume":"86","author":"DC Danila","year":"2001","unstructured":"Danila DC, et al. Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph Tumors 10.1210\/jc.86.7.2976. J Clin Endocrinol Metab 2001;86(7):2976\u201381.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9082_CR54","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1530\/acta.0.1200760","volume":"120","author":"SW Lamberts","year":"1989","unstructured":"Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201\u2013995 on ACTH secretion in Nelson\u2019s syndrome and Cushing\u2019s disease. Acta Endocrinol (Copenh) 1989;120(6):760\u20136.","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"3","key":"9082_CR55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03349555","volume":"13","author":"B Ambrosi","year":"1990","unstructured":"Ambrosi B, et al. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 1990;13(3):257\u201361.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"9082_CR56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jcem-40-6-1125","volume":"40","author":"JB Tyrrell","year":"1975","unstructured":"Tyrrell JB, et al. Inhibition by somatostatin of ACTH secretion in Nelson\u2019s syndrome. J Clin Endocrinol Metab 1975;40(6):1125\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9082_CR57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03347703","volume":"17","author":"L Petrini","year":"1994","unstructured":"Petrini L, et al. Long-term treatment of Nelson\u2019s syndrome by octreotide: a case report. J Endocrinol Invest 1994;17(2):135\u20139.","journal-title":"J Endocrinol Invest"},{"issue":"843","key":"9082_CR58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/pgmj.72.843.53","volume":"72","author":"F Kelestimur","year":"1996","unstructured":"Kelestimur F, et al. The effects of octreotide in a patient with Nelson\u2019s syndrome. Postgrad Med J 1996;72(843):53\u20134.","journal-title":"Postgrad Med J"},{"issue":"4","key":"9082_CR59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11102-005-1404-x","volume":"7","author":"J Hoek van der","year":"2004","unstructured":"van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing\u2019s disease. Pituitary 2004;7(4):257\u201364.","journal-title":"Pituitary"},{"key":"9082_CR60","unstructured":"Boscaro M, Petersenn S, Atkinson AB, Bertherat J, Findling J, Snyder P, McBride K, Reincke M, Ludlam W, Gao B, Melmed S, Freda P, Frohman L, Grossman A, Biller B, Glusman JE. Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing\u2019s disease: preliminary safety and efficacy results of a phase II study. Presented at ENDO 2006, abstr OR9-1, 2006,. Boston, USA."},{"issue":"1","key":"9082_CR61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clpt.2005.04.003","volume":"78","author":"P Ma","year":"2005","unstructured":"Ma P, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 2005;78(1):69\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"9082_CR62","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/en.2002-220219","volume":"143","author":"G Weckbecker","year":"2002","unstructured":"Weckbecker G, et al. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone\/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002;143(10):4123\u201330.","journal-title":"Endocrinology"},{"issue":"4710","key":"9082_CR63","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1126\/science.3892690","volume":"229","author":"T Antakly","year":"1985","unstructured":"Antakly T, et al. Induced expression of the glucocorticoid receptor in the rat intermediate pituitary lobe. Science 1985;229(4710):277\u20139.","journal-title":"Science"},{"key":"9082_CR64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1113\/jphysiol.1991.sp018655","volume":"439","author":"J Stack","year":"1991","unstructured":"Stack J, Surprenant A. Dopamine actions on calcium currents, potassium currents and hormone release in rat melanotrophs. J Physiol 1991;439:37\u201358.","journal-title":"J Physiol"},{"issue":"2","key":"9082_CR65","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1210\/endo-110-2-657","volume":"110","author":"JM Farah Jr.","year":"1982","unstructured":"Farah JM Jr., Malcolm DS, Mueller GP. Dopaminergic inhibition of pituitary beta-endorphin-like immunoreactivity secretion in the rat. Endocrinology 1982;110(2):657\u20139.","journal-title":"Endocrinology"},{"issue":"8","key":"9082_CR66","first-page":"1133","volume":"12","author":"A Saiardi","year":"1998","unstructured":"Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing\u2019s-like syndrome in mice. Mol Endocrinol 1998;12(8):1133\u20139.","journal-title":"Mol Endocrinol"},{"issue":"2","key":"9082_CR67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jcem-54-2-286","volume":"54","author":"SW Lamberts","year":"1982","unstructured":"Lamberts SW, de Lange SA, Stefanko SZ. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing\u2019s disease: differences in the regulation of hormone secretion. J Clin Endocrinol Metab 1982;54(2):286\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9082_CR68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1210\/jcem-68-2-495","volume":"68","author":"RJ Croughs","year":"1989","unstructured":"Croughs RJ, et al. Bromocriptine-responsive Cushing\u2019s disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland. J Clin Endocrinol Metab 1989;68(2):495\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9082_CR69","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI115941","volume":"90","author":"WE Farrell","year":"1992","unstructured":"Farrell WE, et al. Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines. J Clin Invest 1992;90(3):705\u201310.","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"9082_CR70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-5793(94)80387-0","volume":"339","author":"D Yin","year":"1994","unstructured":"Yin D, et al. Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett 1994;339(1\u20132):73\u20135.","journal-title":"FEBS Lett"},{"issue":"5","key":"9082_CR71","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89(5):2452\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9082_CR72","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","volume":"14","author":"L Stefaneanu","year":"2001","unstructured":"Stefaneanu L, et al. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 2001;14(3):329\u201336.","journal-title":"Endocrine"},{"issue":"4","key":"9082_CR73","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/edrv-14-4-443","volume":"14","author":"JW Miller","year":"1993","unstructured":"Miller JW, Crapo L. The medical treatment of Cushing\u2019s syndrome. Endocr Rev 1993;14(4):443\u201358.","journal-title":"Endocr Rev"},{"issue":"2","key":"9082_CR74","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1210\/jcem-51-2-307","volume":"51","author":"SW Lamberts","year":"1980","unstructured":"Lamberts SW, et al. The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing\u2019s disease and Nelson\u2019s syndrome. J Clin Endocrinol Metab 1980;51(2):307\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"9082_CR75","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/BF03343660","volume":"22","author":"R Pivonello","year":"1999","unstructured":"Pivonello R, et al. Complete remission of Nelson\u2019s syndrome after 1-year treatment with cabergoline. J Endocrinol Invest. 1999;22(11):860\u20135.","journal-title":"J Endocrinol Invest."},{"issue":"1","key":"9082_CR76","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1440051","volume":"144","author":"P Petrossians","year":"2001","unstructured":"Petrossians P, et al. ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 2001;144(1):51\u20137.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"9082_CR77","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/BF03345309","volume":"27","author":"T Miyoshi","year":"2004","unstructured":"Miyoshi T, et al. Effect of cabergoline treatment on Cushing\u2019s disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest. 2004;27(11):1055\u20139.","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"9082_CR78","first-page":"300","volume":"62","author":"LA Casulari","year":"2004","unstructured":"Casulari LA, et al. Nelson\u2019s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res. 2004;62(6):300\u20135.","journal-title":"Horm Res."},{"issue":"2","key":"9082_CR79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11102-006-9290-4","volume":"9","author":"I Shraga-Slutzky","year":"2006","unstructured":"Shraga-Slutzky I, Shimon I, Weinshtein R. Clinical and biochemical stabilization of Nelson\u2019s syndrome with long-term low-dose cabergoline treatment. Pituitary. 2006;9(2):151\u20134.","journal-title":"Pituitary."},{"issue":"4","key":"9082_CR80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0003-4266(06)72611-7","volume":"67","author":"F Illouz","year":"2006","unstructured":"Illouz F, et al. [Use of cabergoline in persisting Cushing\u2019s disease]. Ann Endocrinol (Paris) 2006;67(4):353\u20136.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"11","key":"9082_CR81","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.revmed.2007.05.018","volume":"28","author":"C Garcia","year":"2007","unstructured":"Garcia C, et al. [Nelson\u2019s syndrome management: current knowledge]. Rev Med Interne. 2007;28(11):766\u20139.","journal-title":"Rev Med Interne."},{"key":"9082_CR82","unstructured":"Godbout A, B.H., Babin S, Sabourin A, Lacroix A. Cabergoline in the long-term treatment of Cushing\u2019s disease. in The Endocrine Society\u2019s 89th Annual Meeting, June 2\u20135. 2007, Toronto, Canada."},{"key":"9082_CR83","unstructured":"Pivonello R, D.M.M., Faggiano A, De Leo M, Lombardi G, Hofland L, Lamberts S, Colao A. Cabergoline treatment in Cushing\u2019s disease: Effect on hypertension, glucose intolerance and dyslipidemia. in P4\u201350, Endocrine Society\u2019s 89th Annual Meeting, June 2\u20135. 2007, Toronto, Canada."},{"issue":"1","key":"9082_CR84","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356(1):29\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"9082_CR85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, et al. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 2007;356(1):39\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"9082_CR86","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2796.2007.01874.x","volume":"263","author":"VG Rasmussen","year":"2008","unstructured":"Rasmussen VG, et al. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson\u2019s disease. J Intern Med 2008;263(1):90\u20138.","journal-title":"J Intern Med"},{"issue":"Suppl 1","key":"9082_CR87","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1530\/eje.1.02348","volume":"156","author":"A Colao","year":"2007","unstructured":"Colao A, et al. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol 2007;156(Suppl 1):S57\u201363.","journal-title":"Eur J Endocrinol"},{"issue":"3\u20134","key":"9082_CR88","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000095536","volume":"83","author":"A Saveanu","year":"2006","unstructured":"Saveanu A, et al. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006;83(3\u20134):258\u201363.","journal-title":"Neuroendocrinology"},{"issue":"11 Suppl Intern","key":"9082_CR89","first-page":"21","volume":"28","author":"P Jaquet","year":"2005","unstructured":"Jaquet P, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005;28(11 Suppl International):21\u20137.","journal-title":"J Endocrinol Invest"},{"key":"9082_CR90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","volume":"286","author":"HA Schmid","year":"2008","unstructured":"Schmid HA. Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286:69\u201374.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"9082_CR91","first-page":"17","volume":"78","author":"SW Lamberts","year":"1994","unstructured":"Lamberts SW, et al. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing\u2019s syndrome. J Clin Endocrinol Metab 1994;78(1):17\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9082_CR92","first-page":"20","volume":"78","author":"M Phlipponneau","year":"1994","unstructured":"Phlipponneau M, et al. Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 1994;78(1):20\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9082_CR93","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1210\/jcem-68-5-988","volume":"68","author":"X Bertagna","year":"1989","unstructured":"Bertagna X, et al. Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide. J Clin Endocrinol Metab 1989;68(5):988\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"9082_CR94","first-page":"2885","volume":"81","author":"F Vignati","year":"1996","unstructured":"Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J Clin Endocrinol Metab 1996;81(8):2885\u201390.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9082_CR95","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0002-9343(94)90059-0","volume":"96","author":"WW Herder de","year":"1994","unstructured":"de Herder WW, et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing\u2019s syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 1994;96(4):305\u201312.","journal-title":"Am J Med"},{"issue":"4","key":"9082_CR96","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1172\/JCI117143","volume":"93","author":"DW Ray","year":"1994","unstructured":"Ray DW, et al. Human small cell lung cancer cell lines expressing the proopiomelanocortin gene have aberrant glucocorticoid receptor function. J Clin Invest 1994;93(4):1625\u201330.","journal-title":"J Clin Invest"},{"issue":"9","key":"9082_CR97","first-page":"1193","volume":"9","author":"D Gaitan","year":"1995","unstructured":"Gaitan D, et al. Glucocorticoid receptor structure and function in an adrenocorticotropin-secreting small cell lung cancer. Mol Endocrinol 1995;9(9):1193\u2013201.","journal-title":"Mol Endocrinol"},{"issue":"8","key":"9082_CR98","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/BF03347351","volume":"26","author":"GI Uwaifo","year":"2003","unstructured":"Uwaifo GI, et al. Is there a therapeutic role for octreotide in patients with ectopic Cushing\u2019s syndrome? J Endocrinol Invest 2003;26(8):710\u20137.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"9082_CR99","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1210\/jcem-67-5-1080","volume":"67","author":"SW Lamberts","year":"1988","unstructured":"Lamberts SW, et al. Successful treatment with SMS 201-995 of Cushing\u2019s syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma. J Clin Endocrinol Metab 1988;67(5):1080\u20133.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9082_CR100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24(1):28\u201347.","journal-title":"Endocr Rev"},{"issue":"1","key":"9082_CR101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1210\/jc.2006-0728","volume":"92","author":"R Pivonello","year":"2007","unstructured":"Pivonello R, et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007;92(1):65\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9082_CR102","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jc.2003-030859","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 2004;89(4):1674\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"9082_CR103","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJM200506093522322","volume":"352","author":"R Pivonello","year":"2005","unstructured":"Pivonello R. Cabergoline plus lanreotide for ectopic Cushing\u2019s syndrome. N Engl J Med 2005;352(23):2457\u20138.","journal-title":"N Engl J Med"},{"key":"9082_CR104","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2265.2007.03124.x","volume":"68","author":"N Unger","year":"2008","unstructured":"Unger N, et al. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumors. Clin Endocrinol (Oxf) 2008;68:850\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"9082_CR105","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1055\/s-2005-921092","volume":"37","author":"B Ueberberg","year":"2005","unstructured":"Ueberberg B, et al. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005;37(12):722\u20138.","journal-title":"Horm Metab Res"},{"issue":"4","key":"9082_CR106","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1081\/ERC-200044161","volume":"30","author":"N Unger","year":"2004","unstructured":"Unger N, et al. Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors. Endocr Res 2004;30(4):931\u20134.","journal-title":"Endocr Res"},{"issue":"8 Suppl 1","key":"9082_CR107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0026-0495(96)90091-8","volume":"45","author":"WW Herder de","year":"1996","unstructured":"de Herder WW, Lamberts SW. Is there a role for somatostatin and its analogs in Cushing\u2019s syndrome? Metabolism 1996;45(8 Suppl 1):83\u20135.","journal-title":"Metabolism"},{"issue":"Suppl 8","key":"9082_CR108","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/00005344-198900148-00004","volume":"14","author":"C Missale","year":"1989","unstructured":"Missale C, et al. Dopaminergic receptor mechanisms modulating the renin-angiotensin system and aldosterone secretion: an overview. J Cardiovasc Pharmacol 1989;14(Suppl 8):S29\u201339.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"9082_CR109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/eje.0.1310091","volume":"131","author":"F Amenta","year":"1994","unstructured":"Amenta F, et al. Pharmacological characterization and autoradiographic localization of dopamine receptors in the human adrenal cortex. Eur J Endocrinol 1994;131(1):91\u20136.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"9082_CR110","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1210\/jcem.86.9.7859","volume":"86","author":"KD Wu","year":"2001","unstructured":"Wu KD, et al. Expression and localization of human dopamine D2 and D4 receptor mRNA in the adrenal gland, aldosterone-producing adenoma, and pheochromocytoma. J Clin Endocrinol Metab 2001;86(9):4460\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9082_CR111","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1210\/jc.2003-031746","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab 2004;89(9):4493\u2013502.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"9082_CR112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004;80(Suppl 1):47\u201350.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"9082_CR113","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi A, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)\/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002;303(2):805\u201314.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"9082_CR114","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/eje.1.01950","volume":"153","author":"P Jaquet","year":"2005","unstructured":"Jaquet P, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153(1):135\u201341.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"9082_CR115","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","volume":"89","author":"LJ Hofland","year":"2004","unstructured":"Hofland LJ, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004;89(4):1577\u201385.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-008-9082-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T12:08:55Z","timestamp":1709122135000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11154-008-9082-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,19]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9082"],"URL":"https:\/\/doi.org\/10.1007\/s11154-008-9082-4","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,19]]}}}